Related Experiment Video
Updated: Jul 22, 2026
11:14
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Cisplatin carbonato complexes. Implications for uptake, antitumor properties, and toxicity
Corey R Centerwall1, Jerry Goodisman, Deborah J Kerwood
1Department of Chemistry, Syracuse University, CST 1-014, Syracuse, New York 13244-4100, USA.
Journal of the American Chemical Society
|September 15, 2005
Summary
Cisplatin reacts with carbonate in biological fluids, forming monochloro and biscarbonato complexes. These species may impact cisplatin
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Biochemistry
Background:
- Cisplatin is a widely used platinum-based chemotherapy drug.
- Culture media and blood contain carbonate ions.
- Understanding cisplatin's reactivity in biological environments is crucial.
Purpose of the Study:
- To investigate the reaction products of aquated cisplatin with carbonate.
- To characterize the formation of carbonato species under physiological conditions.
- To explore the potential impact of these species on cisplatin's therapeutic efficacy.
Main Methods:
- Studied the reaction kinetics of aquated cisplatin with carbonate.
- Characterized the intermediate and final complexes formed.
- Simulated physiological conditions relevant to cancer therapy.
Main Results:
- The initial reaction yields a monochloro monocarbonato cisplatin species.
- Prolonged exposure to carbonate leads to the formation of a biscarbonato complex.
- These carbonato complexes are formed under simulated therapeutic conditions.
Conclusions:
- The formation of carbonato species is a significant reaction pathway for cisplatin in biological media.
- These species may influence cisplatin's cellular uptake and distribution.
- Altered species could affect cisplatin's antitumor activity and toxicity profile.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...